Nurse Liaison (KNL) at Karyopharm Therapeutics in Remote

Role Overview & Key Functions:

The Nurse Liaison role (KNL) is a field-based position comprised of nurses reporting to the Head of Sales. The KNL partners with their commercial team members, sales, marketing, managed markets, patient advocacy, as well as medical counterparts, and medical affairs. The KNL will be responsible for establishing strategic relationships with key customers, local and regional advocacy organizations and the oncology nursing community. This collaborative approach will serve to provide education, enhanced clinical care, and the opportunity to build strategic relationships with both key customers and Karyopharm internal customers. The KNL educates and trains clinical personnel in the delivery of therapies, patient treatment management, and related clinical topics in support of the Karyopharm field sales team.

RESPONSIBILITIES:

• Represent specified Karyopharm Therapeutics products in the medical community for an assigned geographical area in accordance with Karyopharm’s direction and policy, focused on the nursing segment
• Deliver approved product and disease state-related education to healthcare professionals (HCPs) within assigned geographic region
• Develop strong long-term relationships with clinical personnel, advanced practice provider opinion leaders, key nurse opinion leaders, advocacy organizations, key nursing organizations, and societies focused on the nursing segment
• Work cross-functionally as part of an integrated team to identify and access key customers, assess their education needs, and provide clinical and educational support
• Collaborate with Karyopharm counterparts to identify and access key customers. Communicate and coordinate KNL efforts with Regional Business Directors, Hematology-Oncology Specialists, Patient Advocacy, Market Access, and other corporate colleagues as part of an integrated team following all compliance and regulatory guidelines, to ensure customer needs are addressed
• Develop and execute geographical-based strategic and tactical plans to meet customer and business needs
• Work closely with marketing to identify and develop nursing specific tools to fulfill the needs of the customer
• Executes external disease state educational presentations and on label product presentations for dinner programs, round tables, and society presentations. Provide in-office/in-hospital educational presentations to key customers reactively in response to an identified need/request for clinical information. Additional presentations for nursing groups, societies, and various patient support groups, including patients and caregivers, on disease state and Karyopharm Therapeutics marketed products, utilizing on label approved slide decks may also be completed by the KNL.
• Identify and communicate field issues, opportunities and compelling activities through appropriate organizational venues
• Partner with key commercial and medical personnel to ensure appropriate and compliant utilization of product and disease state education and resources
• Maintain an open dialogue with key opinion leaders in the nursing arena and develop product champions for promoted projects
• Perform all administrative functions of the position in a timely and efficient manner and in accordance with Karyopharm Therapeutics policies and procedures.

Candidate Profile & Requirements:

QUALIFICATIONS:

• Minimum of a BSN, RN required.
• Advanced degree preferred
• 5 years hematology/oncology clinical experience
• 3+ years in the pharmaceutical industry
• OCN preferred
• Strong clinical expertise and ability to articulate complex information to internal and external stakeholders
• Experience in working/leading cross-functional teams to coordinate and execute plans and projects
• Demonstrates expert knowledge in related disease states and the ability to serve as a technical and clinical resource to the nursing community
• Excellent written and oral communication skills
• Strong interpersonal and presentation skills
• Experience in targeting, developing and maintaining a customer base
• Experience in building customer relationships with key nursing organizations, targeted accounts, state societies and other identified key customers
• Demonstrates a working knowledge of FDA, HIPPA regulations and approved guidelines for pharmaceutical promotion and adverse event/drug reaction reporting, medical education guidance and compliance policies
• Established record of consistent achievements of goals and objectives
• Demonstrated track record of achieving/exceeding responsibilities, goals and objectives
• Demonstrates an in-depth knowledge of the oncology market
• Self-motivated, reliable and ability to function independently within a team
• Valid driver's license and the ability to travel up to 70% regionally including some overnight and weekend commitments

At Karyopharm, base pay is one part of a competitive total rewards package that includes comprehensive benefits (medical, dental, vision, 401(k), and more), equity and the potential to receive annual target bonuses. Actual pay is based on factors such as location, experience, skills, education, and internal equity. We maintain broad salary ranges to reflect market conditions and the specialized nature of our work. The anticipated base salary range for this position is $175K-$195K USD.

Our Value Proposition:

This is a uniquely exciting time to join Karyopharm Therapeutics where we are pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. We are building upon an established commercial foundation in multiple myeloma while advancing the potential of selinexor across additional hematologic and solid tumor cancers including myelofibrosis and TP53 wild-type endometrial cancer, areas where patients continue to face significant unmet needs.

Our lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is approved in the U.S. for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 countries and territories outside the U.S. We are also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor.

As we prepare for our next phase of growth, we are continuing to invest in critical capabilities across the organization to support future opportunities and deepen our impact in oncology. We are looking for talented people who are motivated by meaningful work, energized by growth and momentum, and excited by the opportunity to help shape what comes next in a collaborative, fast-moving environment where individual contributions are visible and valued.

Learn more at Karyopharm Therapeutics.